摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-O-acetyl-2-deoxy-4,6-O-isopropylidene-2-trichloroacetamido-α/β-D-glucopyranose trichloroacetimidate | 1061181-32-5

中文名称
——
中文别名
——
英文名称
3-O-acetyl-2-deoxy-4,6-O-isopropylidene-2-trichloroacetamido-α/β-D-glucopyranose trichloroacetimidate
英文别名
3-O-acetyl-2-deoxy-4,6-O-isopropylidene-2-(2,2,2-trichloroacetamido)-D-glucopyranosyl 2,2,2-trichloroacetimidate;[(4aR,7R,8R,8aS)-2,2-dimethyl-7-[(2,2,2-trichloroacetyl)amino]-6-(2,2,2-trichloroethanimidoyl)oxy-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-8-yl] acetate
3-O-acetyl-2-deoxy-4,6-O-isopropylidene-2-trichloroacetamido-α/β-D-glucopyranose trichloroacetimidate化学式
CAS
1061181-32-5
化学式
C15H18Cl6N2O7
mdl
——
分子量
551.035
InChiKey
XFDZXOJUPUGSOM-WWGUJXLXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.75±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    30
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.8
  • 拓扑面积:
    116
  • 氢给体数:
    2
  • 氢受体数:
    8

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X
    摘要:
    本发明涉及从糖类衍生的化合物,其重现志贺氏菌弗氏菌血清型3a和X的表位,并且涉及将其用于制备疫苗组合物。更具体地,本发明涉及包括下文描述的寡糖或多糖的新型糖结合化合物,用于合成这些寡糖或多糖和糖结合物的方法,这些寡糖或多糖的衍生物,含有这些衍生物的组合物,以及将糖结合物用于疫苗目的的用途。最后,本发明涉及使用一个或多个寡糖或多糖或其结合物诊断志贺氏菌弗氏菌感染的方法。
    公开号:
    US08815239B2
  • 作为产物:
    描述:
    3-O-acetyl-2-deoxy-4,6-O-isopropylidene-2-(2,2,2-trichloroacetamido)-D-glucopyranose 、 三氯乙腈1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下, 以 1,2-二氯乙烷 为溶剂, 以87%的产率得到3-O-acetyl-2-deoxy-4,6-O-isopropylidene-2-trichloroacetamido-α/β-D-glucopyranose trichloroacetimidate
    参考文献:
    名称:
    Efficient route to orthogonally protected precursors of 2-acylamino-2-deoxy-3-O-substituted-β-d-glucopyranose derivatives and use thereof
    摘要:
    An efficient route to two 3-O-acyl-2-deoxy-4,6-O-isopropylidene-2-trichloroacetamido-D-glucopyranosyl trichloroacetimidate donors is reported. As demonstrated for the 3-O-acetyl derivative, these building blocks are exquisite beta-D-glucosamine donors when reacted either with simple alcohols or with complex oligosaccharides. Besides, their protection pattern is compatible with selective deprotection and subsequent chain elongation at O-3 of the newly incorporated glucosamine residue. (C) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetlet.2008.06.052
点击查看最新优质反应信息

文献信息

  • Synthesis of Two Tetra- and Four Pentasaccharide Fragments of<i>Shigella flexneri</i>Serotypes 3a and X O-Antigens from a Common Tetrasaccharide Intermediate
    作者:Julien Boutet、Laurence A. Mulard
    DOI:10.1002/ejoc.200800693
    日期:2008.11
    Ac→2]-α-L-Rhap-(1→3)-β-D-GlcpNAc-(1→}n ((E)ABAcCD)n polymer were synthesized as their propyl glycosides by use of a common fully protected (E)ABAcC intermediate (9). Tetrasaccharide 9 derived from the condensation of an EA donor and a BAcC acceptor. Partial and full deprotection gave free tetrasaccharides (E)ABAcC and (E)ABC, respectively. Alternatively, 9 was converted into a trichloroacetimidate
    所得受体与 D 供体的糖基化,以及随后的部分或全部脱保护,得到支链五糖 D(E)ABAcC 和 D(E)ABC。所有目标都是志贺氏菌 3a 的 O 抗原的一部分,这是一种流行的血清型。非 O-乙酰化寡糖由 S.flexneri 血清型 X O-抗原共有。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2008)
  • GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X
    申请人:Mulard Laurence
    公开号:US20100239584A1
    公开(公告)日:2010-09-23
    The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.
    本发明涉及从糖类衍生的化合物,这些化合物重现Shigella flexneri血清型3a和X的表位,并且用于制备疫苗组合物。更具体地,本发明涉及包含下文描述的寡糖多糖的新型糖结合化合物,用于合成这些寡糖多糖和糖结合物的方法,这些寡糖多糖的衍生物,含有这些化合物的组合物,以及将糖结合物用于疫苗目的的用途。最后,本发明涉及使用一个或多个寡糖多糖或其共轭物诊断Shigella flexneri感染的方法。
  • Efficient Synthesis of Six Tri- to Hexasaccharide Fragments of <i>Shigella flexneri</i> Serotypes 3a and/or X O-Antigen, Including a Study on Acceptors Containing <i>N</i>-Trichloroacetylglucosamine versus <i>N</i>-Acetylglucosamine
    作者:Julien Boutet、Catherine Guerreiro、Laurence A. Mulard
    DOI:10.1021/jo802127z
    日期:2009.4.3
    resulting hexasaccharide provided BAcCD(E)AB and BCD(E)AB, respectively. All of the synthesized oligosaccharides are parts of the O-antigen of Shigella flexneri 3a, a prevalent serotype. Moreover, the non-O-acetylated fragments are also parts of the S. flexneri serotype X O-antigen.
    六三-到六糖的片断的2) - [α- d -Glc p - (1→3)] - α-升-RHA p - (1→2)-α-升-RHA p - (1→ 3)-[Ac→2] -α -1 - Rha p-(1→3)-β- d- Glc p NAc-(1→} n聚合物([ (E)AB Ac CD ] n)的合成他们丙基苷。所有目标共享(E)AB序列,继使用彻查ň -trichloroacetylglucosamine-与ñ含3-乙酰基葡糖胺的三糖和四糖受体,成功的策略是基于三乙酰亚酸酯化学,用作永久性N保护的三乙酰基和作为所选结构单元的临时和/或永久异头保护基的烯丙糖苷配基的有效组合。使用在2 A处正交保护的EAB中间体可提供三糖靶标和受体12,将其与链终止剂D缩合,然后完全脱保护,得到四糖D(E)AB。或者,用D逐步将12糖基化供体在位置3的选择性去块兼容d和2- ö乙酰Ç施主以下OH-3的
  • Synthesis of branched tri- to pentasaccharides representative of fragments of Shigella flexneri serotypes 3a and/or X O-antigens
    作者:Julien Boutet、Catherine Guerreiro、Laurence A. Mulard
    DOI:10.1016/j.tet.2008.08.080
    日期:2008.11
    Final Pd/C-mediated deprotection, run under a high pressure of hydrogen, ensured O-acetyl stability. All targets are parts of the O-antigen of Shigella flexneri 3a, a prevalent serotype. Non-O-acetylated oligosaccharides are shared by the S. flexneri serotype X O-antigen.
    的2)的片段- [α-d-GLC p - (1→3)] - α-L-鼠李糖p - (1→2)-α-L-鼠李糖p - (1→3) - [AC →2]-α-L-鼠李糖p - (1→3)-β-d-GLC p NAc-(1→} ñ((E)AB AC CD)ñ。聚合物合成d(E)甲,CD (E)A,Ac CD(E)A是根据线性策略获得的,而BCD(E)A和B Ac CD(E)A是由适当的BC和D(E)A的缩合得到的建筑模块。寡糖合成为自己丙基糖苷,依靠(i)所述有效三化学,(ⅱ)共同EA烯丙基糖苷,和(iii)2 -向残余物trichloroacetamido-d-D-吡喃葡萄糖前体d。在氢气的高压下进行的最终Pd / C介导的脱保护,确保了O-乙酰基的稳定性。所有的靶标都是弗氏志贺氏菌3a(一种流行的血清型)的O-抗原的一部分。弗氏链球菌血清型X O-抗原共有非O-乙酰化的寡糖
  • GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X
    申请人:INSTITUT PASTEUR
    公开号:US20150050282A1
    公开(公告)日:2015-02-19
    The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.
    本发明涉及从糖衍生物中复制Shigella flexneri 3a和X血清型表位的化合物,以及用于制备疫苗组分的使用方法。更具体地说,本发明的主题涉及新型糖连接化合物,包括下文描述的寡糖多糖,以及合成这些寡糖多糖和糖连接物的方法,这些寡糖多糖的衍生物,含有它们的组合物,以及将糖连接物用于疫苗接种目的的用途。最后,本发明涉及使用一种或多种寡糖多糖或其共轭物来诊断Shigella flexneri感染的方法。
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)